Physician profile
Vivek Singam
NPI 1134789985
$4,532.13
in general payments reported to CMS, 2019-2025
22 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2023: $391 · 2024: $2,397 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $617.86 | 2024-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $569.36 | 2024-2025 | Tremfya |
| Abbvie INC. | $564.57 | 2023-2024 | Rinvoq, Botox, Skyrizi |
| Pfizer INC. | $397.76 | 2024-2025 | |
| Journey Medical Corporation | $320.58 | 2024-2025 | |
| Amgen INC. | $304.84 | 2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $284.47 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $199.16 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $190.78 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $165.87 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.97 | 2025 | Spevigo |
| Incyte Corporation | $143.40 | 2024-2025 | Opzelura |
| Allergan, INC. | $137.70 | 2019 | |
| Ucb, INC. | $122.02 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $106.71 | 2025 | Ebglyss, Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polarityte, INC. | $96.93 | 2019 | |
| Genzyme Corporation | $60.83 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $29.18 | 2023-2024 | Ilumya |
| Dermavant Sciences, INC. | $14.90 | 2024 | Vtama |
| Botanix Sb INC | $14.85 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $14.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Singam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.